share_log

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD: Others

Clearmind Medicine | UPLOAD:其他
SEC announcement ·  02/14 22:16
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.
Clearmind Medicine Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on February 7, 2024, will not undergo review by the commission. The SEC's communication, dated February 14, 2024, was addressed to Dr. Adi Zuloff-Shani, the Chief Executive Officer of Clearmind Medicine. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. Clearmind Medicine was directed to Rules 460 and 461 should they wish to request acceleration of the registration process. The SEC provided contact information for further inquiries, directing them to Cindy Polynice.
美国证券交易委员会(SEC)已告知生物技术公司Clearmind Medicine Inc.,其于2024年2月7日提交的F-1表格注册声明不会经过该委员会的审查。美国证券交易委员会于2024年2月14日发给了Clearmind Medicine首席执行官阿迪·祖洛夫-沙尼博士。美国证券交易委员会还提醒该公司,无论美国证券交易委员会的审查程序如何,其对披露的准确性和充分性负有责任。如果Clearmind Medicine希望申请加快注册程序,则应遵循第460和461条。美国证券交易委员会提供了进一步调查的联系信息,并将其定向到辛迪·波利尼斯。
美国证券交易委员会(SEC)已告知生物技术公司Clearmind Medicine Inc.,其于2024年2月7日提交的F-1表格注册声明不会经过该委员会的审查。美国证券交易委员会于2024年2月14日发给了Clearmind Medicine首席执行官阿迪·祖洛夫-沙尼博士。美国证券交易委员会还提醒该公司,无论美国证券交易委员会的审查程序如何,其对披露的准确性和充分性负有责任。如果Clearmind Medicine希望申请加快注册程序,则应遵循第460和461条。美国证券交易委员会提供了进一步调查的联系信息,并将其定向到辛迪·波利尼斯。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息